Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · MD, CA, NC, TX, MA · Jul 15, 2009 → Jul 22, 2014
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 3:02 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET
Ed Mathers is listed as a director on 35 SEC Form D filings by 13 issuers between Jul 2009 and Dec 2020. Largest by amount reported sold: INTARCIA THERAPEUTICS, INC (Boston, MA — biotechnology — 2009–2012; $524.6M reported sold to 90 investors), Akouos, Inc. (Boston, MA — biotechnology — 2017–2020; $105.1M reported sold to 33 investors), Amplyx Pharmaceuticals, Inc. (San Diego, CA — pharmaceuticals — 2015; $91.3M reported sold to 28 investors), SYNLOGIC, INC. (Cambridge, MA — biotechnology — 2015; $80M reported sold to 24 investors), Mirum Pharmaceuticals, Inc. (Foster City, CA — biotechnology — 2018; $68.5M reported sold to 14 investors) and 8 more (all listed below).
What this means That is a lot of deals — 13 separate companies raised money with this person listed as director, over about 11 years. Across those companies the filings report $1.09B sold in total.
Listed alongside Barbara McClung (11 shared filings), David J. Franklin (11 shared filings), Glen Sato (11 shared filings), Irwin Scher (11 shared filings), James Niedel (11 shared filings) and 84 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Ed. Each name links to their own page.
The issuers belong to 4 sponsor groups: Synlogic (3 issuers, $139.1M reported sold, 2011–2019), Envisia Therapeutics (5 issuers, $71.8M reported sold, 2009–2021), Senti Biosciences (2 issuers, $49.4M reported sold, 2018–2026) and Onkure (2 issuers, $118.8M reported sold, 2011–2024).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 35 public filings for Ed Mathers and found 11 differences, 3 worth asking the sponsor about: Regulator action naming a team member: Ankit Mahadevia and Satyavrat Shukla (Jan 16, 2026); Ed Mathers appears on 3 deals that stopped filing before reaching their target; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Ed Mathers has not run yet — it is joining a line of 59,052 names; searches run around the clock at the hosts' allowed rate. Searched so far: 668 names.
Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.
Five things investors ask first. Items still in human review are counted, not shown.
None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 3:02 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Ed Mathers..
State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).
None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 3:02 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
11 differences found between the filings for Ed Mathers — 3 worth asking about (compared 35 filings on Oct 24, 2026)
A ap release dated Jan 16, 2026 names Ankit Mahadevia (listed on the same filings). The release is the source; we do not summarize its outcome here.
What this means A regulator filed or announced an action naming this person or company (or someone on the same filings). Read the release; ask the sponsor what it was and how it ended.
United States Bankruptcy Court, D. Massachusetts docket "Khuong Tran and Vien T. Nguyen" filed Oct 14, 2003, closed Mar 22, 2006. Chau Khuong (listed on the same filings) is listed as Debtor ("Khuong Tran and Vien T. Nguyen"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
The Oct 19, 2015 Form D reports $4,600,000 sold and $500,000 of the proceeds used for payments to officers, directors or promoters (marked as an estimate).
What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.
Liquidia Technologies Inc (last filing Jan 7, 2020; $25,500,000 sold of $53,312,680); Synlogic, LLC (last filing Feb 26, 2016; $17,116,500 sold of $40,594,970); Envisia Therapeutics Inc. (last filing Nov 22, 2013; $15,213,112 sold of $69,380,195). Each has no filing in more than two years and reported under half its target sold.
What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.
Form D filed 111 days after the first sale — Curzion Pharmaceuticals, Inc. · Form D filed 17 days after the first sale — SENTI BIOSCIENCES, INC. · Form D filed 17 days after the first sale — OnKure Therapeutics, Inc. · Form D filed 17 days after the first sale — Akouos, Inc. · Form D filed 18 days after the first sale — Envisia Therapeutics, Inc. · and 3 more
What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.
No amendment in the last 12 months on an offering that may still be open — OnKure Therapeutics, Inc. (latest filing Dec 21, 2020) · No amendment in the last 12 months on an offering that may still be open — Mirum Pharmaceuticals, Inc. (latest filing Nov 20, 2018) · No amendment in the last 12 months on an offering that may still be open — Akouos, Inc. (latest filing Aug 1, 2018) · No amendment in the last 12 months on an offering that may still be open — SENTI BIOSCIENCES, INC. (latest filing Feb 26, 2018) · No amendment in the last 12 months on an offering that may still be open — OnKure Therapeutics, Inc. (latest filing Jan 8, 2018) · and 10 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
Offering amount changed between filings — Amplyx Pharmaceuticals, Inc. · Offering amount changed between filings — INTARCIA THERAPEUTICS, INC · Offering amount changed between filings — Liquidia Technologies Inc · Offering amount changed between filings — INTARCIA THERAPEUTICS, INC · Offering amount changed between filings — INTARCIA THERAPEUTICS, INC · and 3 more
What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.
"Other" (Jul 15, 2009 to Mar 3, 2011); then "Biotechnology" (Jul 2, 2012).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
This page covers filings where the address state is MD or CA or NC or TX or MA. A separate record, "Ed Mathers" with address state CT, is listed on 2 filings — most recently by Trevi Therapeutics, Inc. (Sep 5, 2018). The two records do not overlap in time: this page runs Jul 15, 2009 to Jul 22, 2014; the other runs Jul 24, 2017 to Sep 5, 2018.
What this means Could be the same person who moved, or two people with the same name. We keep them apart until a filing ties them together. Check both pages before you decide.
The people listed on the Nov 13, 2017 filing give Brookline, MA; on the Aug 1, 2018 filing they give Boston, MA.
What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.
MD on 16 filings (Jul 15, 2009 to Jul 22, 2014); CA on 9 filings (Dec 2, 2009 to Dec 21, 2020); NC on 3 filings (Nov 22, 2013 to Mar 17, 2016); TX on 1 filing (May 1, 2015); MA on 6 filings (Feb 26, 2016 to Mar 3, 2020).
What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.
0 of 27 offerings report sales commissions; 0 report finder's fees; 5 report proceeds to related persons totalling $2,530,000. (includes amounts the issuer reported as estimates)
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| Dec 21, 2020 D OnKure Therapeutics, Inc. File 021-383843 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 3, 2020 D Akouos, Inc. File 021-361803 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 15, 2019 D Curzion Pharmaceuticals, Inc. File 021-344286 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 14, 2019 D OnKure Therapeutics, Inc. File 021-339502 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 20, 2018 D Mirum Pharmaceuticals, Inc. File 021-326260 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 1, 2018 D Akouos, Inc. File 021-318301 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 26, 2018 D SENTI BIOSCIENCES, INC. File 021-306382 | $0 | $0 | $400,000 (est.) The issuer anticipates that it will use a portion of the proceeds of the offering to pay compensation, which is currently expected to be approximately $400,000 per year in the aggregate, for the two executive officers named in Item 3 above. | None listed on this filing | EDGAR ↗ |
| Jan 8, 2018 D OnKure Therapeutics, Inc. File 021-302643 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 13, 2017 D Akouos, Inc. File 021-298512 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 26, 2017 D SYNLOGIC, INC. File 021-287588 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 17, 2016 D Envisia Therapeutics, Inc. File 021-259444 | $0 | $0 | $500,000 (est.) | None listed on this filing | EDGAR ↗ |
| Feb 26, 2016 D Synlogic, LLC File 021-258209 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 26, 2016 D Synlogic, LLC File 021-258214 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 24, 2015 D/A Amplyx Pharmaceuticals, Inc. File 021-251044 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 19, 2015 D Envisia Therapeutics, Inc. File 021-249607 | $0 | $0 | $500,000 (est.) | None listed on this filing | EDGAR ↗ |
| May 1, 2015 D SYNLOGIC, INC. File 021-239002 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 22, 2014 D SYNLOGIC, INC. File 021-221509 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 22, 2013 D Envisia Therapeutics Inc. File 021-206825 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 29, 2012 D INTARCIA THERAPEUTICS, INC File 021-187634 | $0 | $0 | $0 Working capital and general corporate purposes. | None listed on this filing | EDGAR ↗ |
| Nov 29, 2012 D INTARCIA THERAPEUTICS, INC File 021-187635 | $0 | $0 | $0 Repayment of debt. | None listed on this filing | EDGAR ↗ |
| Nov 29, 2012 D INTARCIA THERAPEUTICS, INC File 021-187654 | $0 | $0 | $0 Working capital and general corporate purposes. | None listed on this filing | EDGAR ↗ |
| Aug 30, 2012 D/A INTARCIA THERAPEUTICS, INC File 021-147387 | $0 | $0 | $0 Working capital and general corporate purposes. | None listed on this filing | EDGAR ↗ |
| Aug 22, 2012 D INTARCIA THERAPEUTICS, INC File 021-183097 | $0 | $0 | $0 Working capital and general corporate purposes. | None listed on this filing | EDGAR ↗ |
| Jul 2, 2012 D/A Liquidia Technologies Inc File 021-156174 | $0 | $0 | $480,000 (est.) | None listed on this filing | EDGAR ↗ |
| May 25, 2010 D/A Liquidia Technologies Inc File 021-78167 | $0 | $0 | $650,000 (est.) | None listed on this filing | EDGAR ↗ |
| May 14, 2010 D INTARCIA THERAPEUTICS, INC File 021-142088 | $0 | $0 | $0 Proceeds will be used for working capital. | None listed on this filing | EDGAR ↗ |
| Jan 15, 2010 D/A INTARCIA THERAPEUTICS, INC File 021-56548 | $0 | $0 | $0 Proceeds will be used for working capital. | None listed on this filing | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Ed Mathers on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $65M from 20 investors (69% of the $94.8M target) as of the latest filing. Ed is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $105.1M from 33 investors (100% of the $105.1M target) as of the latest filing. Ed is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $3.5M from 8 investors (100% of the $3.5M target) as of the latest filing. Ed is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $68.5M from 14 investors (57% of the $120.1M target) as of the latest filing. Ed is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $39.4M from 26 investors (74% of the $53.4M target) as of the latest filing. Ed is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $42M from 16 investors (100% of the $42M target) as of the latest filing. Ed is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $10.1M from 9 investors (61% of the $16.5M target) as of the latest filing. Ed is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $17.1M from 3 investors (100% of the $17.1M target) as of the latest filing. Ed is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $91.3M from 28 investors (100% of the $49.2M target) as of the latest filing. Ed is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $80M from 24 investors (100% of the $45M target) as of the latest filing. Ed is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $15.2M from 12 investors (22% of the $69.4M target) as of the latest filing. Ed is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $524.6M from 90 investors (100% of the $160M target) as of the latest filing. Ed is listed as director on 11 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $25.5M from 11 investors (100% of the $13.8M target) as of the latest filing. Ed is listed as director on 5 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
Listed on the same filings as Ed Mathers. Their page shows their other deals.
Kurt Graves is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Stephen Bloch is on 13 issuers in total — a repeat sponsor. Their page lists every one.
Bryan Roberts is on 32 issuers in total — a repeat sponsor. Their page lists every one.
Neal Fowler is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Seth Rudnick is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Michael Grey is on 10 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Ed Mathers. Their page shows their other deals.
Ralph Snyderman is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Isaac Cheng is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Peter Barrett is on 12 issuers in total — a repeat sponsor. Their page lists every one.
Lewis Geffen is on 8 issuers in total — a repeat sponsor. Their page lists every one.
Ankit Mahadevia is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Kush Parmar is on 17 issuers in total — a repeat sponsor. Their page lists every one.
Chau Khuong is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Ed Mathers. Their page shows their other deals.
Mitchell Mutz is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Niall O'Donnell is on 12 issuers in total — a repeat sponsor. Their page lists every one.
One team, 3 deal companies. Ed Mathers is listed on 3 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Ed Mathers.
One team, 5 deal companies. Ed Mathers is listed on 3 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Ed Mathers.
One team, 2 deal companies. Ed Mathers is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Ed Mathers.
One team, 2 deal companies. Ed Mathers is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Ed Mathers.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); KY (Kentucky Secretary of State — Business Entity Search (sosbes.sos.ky.gov), searched by issuer name, data as of Oct 24, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).
None of the 13 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Ed Mathers by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 13 issuers this person is listed on — nothing matched.
Websites and social links of the issuers Ed Mathers is listed on: none on file. No website or social profile named in Mirum Pharmaceuticals, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #43,728 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (Foster City, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Ed Mathers appears on a new Form D, or when a court case or SEC action is matched to them. See plans →
